State of the Heart TAVR

Transcatheter aortic valve replacement (TAVR).

Severe aortic stenosis is a heart valve condition that restricts blood flow out of the heart.   Many of these patients are elderly, with serious medical conditions that prevent them from receiving a valve replacement with conventional open heart surgery.  Research shows that a large percentage of these patients who do not receive treatment for severe aortic stenosis will die within 1-2 years of having symptoms, such as shortness of breath, chest pain, or fainting.

Transcatheter aortic valve replacement (TAVR), has been approved by the FDA for treatment of severe aortic stenosis in patients who are too high risk for conventional open heart surgery.  In this procedure, specialists insert a new valve into the heart from the artery of a patient's leg, instead of doing an open heart surgery which may be associated with higher risk for patients with advanced age or severe medical conditions.

One of the first MHVI patients to undergo this procedure was a 90 year old woman who was discharged from the Mercy Hospital just 2 days later.  The TAVR program at MHVI was created by the teamwork of interventional cardiologists, cardiovascular surgeons, and state-or-the-art cardiovascular imaging specialists, and complements the nationally recognized open heart surgery valve program already put in place by our cardiologists and surgeons.  

Our TAVR program is part of the valvular and structural heart disease program within Allina Health, a collaboration with our partners at the Minneapolis Heart Institute at Abbott Northwestern Hospital and United Heart and Vascular Clinic.

See video animation of this new life-saving therapy.

Media